Concord Biotech Limited (NSE: CONCORDBIO)
India
· Delayed Price · Currency is INR 1,948.55
+48.10 (2.53%)
Oct 9, 2024, 3:30 PM IST
Concord Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 |
| Revenue | 10,379 | 10,169 | 8,532 | 7,129 | 6,169 | 5,123 |
| Revenue Growth (YoY) | 19.71% | 19.20% | 19.67% | 15.56% | 20.42% | - |
| Cost of Revenue | 2,527 | 2,448 | 1,921 | 1,719 | 1,169 | 1,381 |
| Gross Profit | 7,852 | 7,722 | 6,611 | 5,410 | 5,000 | 3,742 |
| Selling, General & Admin | 1,265 | 1,231 | 1,103 | 956.96 | 694.73 | 622.46 |
| Other Operating Expenses | 2,093 | 2,087 | 1,969 | 1,662 | 1,001 | 965.85 |
| Operating Expenses | 3,895 | 3,854 | 3,612 | 3,120 | 1,976 | 1,803 |
| Operating Income | 3,958 | 3,868 | 2,999 | 2,290 | 3,024 | 1,940 |
| Interest Expense | -20.4 | -25.52 | -45.1 | -54.84 | -6.66 | -6.99 |
| Interest & Investment Income | 30.41 | 30.41 | 44.41 | 47.87 | 17.87 | 0.76 |
| Earnings From Equity Investments | -12.98 | 33.71 | 19.59 | -36.38 | -4.49 | 1.5 |
| Currency Exchange Gain (Loss) | 64.81 | 64.81 | 102.22 | 63.59 | 15.51 | 73.57 |
| Other Non Operating Income (Expenses) | 48.94 | 12.41 | 57.93 | 9.73 | 11.25 | 2.85 |
| EBT Excluding Unusual Items | 4,068 | 3,983 | 3,178 | 2,320 | 3,057 | 2,012 |
| Gain (Loss) on Sale of Investments | 140.65 | 140.65 | 37.17 | 52.3 | 69.86 | 124.16 |
| Gain (Loss) on Sale of Assets | 0.12 | 0.12 | -0.94 | -0.34 | - | 0.52 |
| Other Unusual Items | - | - | -0.31 | - | - | - |
| Pretax Income | 4,211 | 4,126 | 3,220 | 2,375 | 3,127 | 2,136 |
| Income Tax Expense | 1,078 | 1,045 | 819.28 | 625.89 | 778.33 | 445.26 |
| Net Income | 3,132 | 3,081 | 2,401 | 1,749 | 2,349 | 1,691 |
| Net Income to Common | 3,132 | 3,081 | 2,401 | 1,749 | 2,349 | 1,691 |
| Net Income Growth | 27.67% | 28.33% | 37.25% | -25.53% | 38.89% | - |
| Shares Outstanding (Basic) | 105 | 105 | 105 | 105 | 105 | 105 |
| Shares Outstanding (Diluted) | 105 | 105 | 105 | 105 | 105 | 105 |
| Shares Change (YoY) | -0.01% | - | - | - | - | - |
| EPS (Basic) | 29.94 | 29.45 | 22.95 | 16.72 | 22.45 | 16.16 |
| EPS (Diluted) | 29.94 | 29.45 | 22.95 | 16.72 | 22.45 | 16.16 |
| EPS Growth | 27.69% | 28.33% | 37.25% | -25.52% | 38.88% | - |
| Free Cash Flow | - | 1,798 | 1,009 | 526.36 | -373.59 | -6.23 |
| Free Cash Flow Per Share | - | 17.18 | 9.65 | 5.03 | -3.57 | -0.06 |
| Dividend Per Share | - | 8.750 | 6.830 | 5.120 | 6.741 | 4.114 |
| Dividend Growth | - | 28.11% | 33.40% | -24.05% | 63.87% | - |
| Gross Margin | 75.65% | 75.93% | 77.49% | 75.89% | 81.05% | 73.05% |
| Operating Margin | 38.13% | 38.03% | 35.15% | 32.12% | 49.01% | 37.87% |
| Profit Margin | 30.18% | 30.30% | 28.14% | 24.54% | 38.07% | 33.01% |
| Free Cash Flow Margin | - | 17.68% | 11.83% | 7.38% | -6.06% | -0.12% |
| EBITDA | 4,474 | 4,386 | 3,527 | 2,778 | 3,287 | 2,141 |
| EBITDA Margin | 43.10% | 43.13% | 41.33% | 38.97% | 53.28% | 41.78% |
| D&A For EBITDA | 516.18 | 518.51 | 527.85 | 487.98 | 263.27 | 200.53 |
| EBIT | 3,958 | 3,868 | 2,999 | 2,290 | 3,024 | 1,940 |
| EBIT Margin | 38.13% | 38.03% | 35.15% | 32.12% | 49.01% | 37.87% |
| Effective Tax Rate | 25.61% | 25.32% | 25.44% | 26.35% | 24.89% | 20.84% |
| Revenue as Reported | 10,753 | 10,507 | 8,885 | 7,364 | 6,308 | 5,436 |
Source: S&P Capital IQ. Standard template. Financial Sources.